The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RI-FLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.
B R I E F R E P O R T

Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center
At the Walter Reed Army Medical Center, there has been an increase in the use of CMS in response to the emergence of multidrug-resistant, gram-negative bacterial infections associated with the wars in Iraq and Afghanistan [14, 15] . The majority of these patients are young and were previously healthy, without underlying risk factors for kidney dysfunction, thus providing a unique cohort to examine the nephrotoxic effects of CMS. The study's objective was to determine the incidence of CMS-associated nephrotoxicity at the Walter Reed Army Medical Center by using a standardized definition of acute renal failure. The RIFLE criteria (risk, injury, failure, loss, and endstage kidney disease) (table 1) are a validated tool to evaluate acute kidney injury, providing a definition from mild renal dysfunction to the need for renal replacement therapy (RRT) [16, 17] .
Methods. The Walter Reed Army Medical Center is a tertiary care medical center in Washington, DC, that cares for active-duty soldiers, their dependents, and retirees. A retrospective review of patients aged у18 years who received intravenous CMS for 172 h from January 2003 through December 2007 was performed. A pharmacy-generated list identified patients who received CMS. Patients were excluded if they were receiving RRT prior to the initiation of CMS treatment. The CMS used in this study was Coly-mycin (Parkedale Pharmaceuticals) and was supplied as 150 mg of colistin base activity per vial (equivalent to 400 mg CMS or 5 million international units) [6] . CMS is given in base activity for the remainder of this article.
Data on demographic characteristics, including weight, were collected for each patient. Data on the indication for CMS, CMS total dose (grams), route of administration, and duration of treatment (days) were collected. Glomerular filtration rate was calculated by the modification of diet in the renal disease equation: 175 ϫ serum creatinine level (Ϫ1.154) ϫ age (Ϫ0.203) ϫ 0.742 (if female). Values for African Americans were adjusted by multiplying by 1.212. During treatment, patients' creatinine levels were monitored at the discretion of the team. Creatinine level was collected at baseline, at 1 week after the last CMS dose ‫27ע(‬ h), and for 3 months ‫1ע(‬ week) for patients with evidence of renal dysfunction at the end of therapy.
The following data were collected for each patient: Acute Physiology and Chronic Health Evaluation II score at the time of CMS administration, use of an aminoglycoside or intravenous radiocontrast agent during or before CMS use, concom- itant vancomycin use, nephrotoxic agents used during CMS therapy, need for vasopressors, death during CMS use, neurotoxicity, and medical comorbidities. Data on proteinuria, the presence of muddy brown casts, and renal tubular epithelial cells were collected. The primary outcome was the cessation of CMS treatment because of nephrotoxocity or because patient met risk, injury, or failure (R, I, or F) criteria secondary to renal toxicity. Secondary outcomes were to determine potential risk factors for renal toxicity.
Statistical analysis was completed using SPSS, version 12.0.1 (SPSS). The change in creatinine level over time was analyzed using repeated-measures analysis of variance, with pairwise comparisons made using the paired t test. Fisher's exact test and the Wilcoxon rank-sum test were used to determine differences between patients with and patients without evidence of renal failure.
was considered to be statistically P ! .05 significant.
Results. A total of 66 patients met the inclusion criteria and were included in the analysis. Fifteen other patients were excluded (3 because of receiving RRT prior to CMS, 1 because of age !18 years, 1 because of receiving only inhaled CMS, and 10 because of receiving !72 h of CMS). Patients were infected mainly by Acinetobacter baumannii and were treated for bac- 14 (21) 13 (20) 11 (19) 14 (28) 3 (12) Injury (I) 9 (14) 10 (15) 10 ( teremia (39%), pneumonia (27%), osteomyelitis (15%), urinary tract infection (5%), central nervous system infection (6%), and other disease (8%). One patient died during the study period. The patients' demographic and clinical characteristics are listed in table 2.
There was a significant change in creatinine level during the first month after the initiation of CMS treatment ( ). P ! .001 Creatinine level increased significantly from baseline to the last dose of CMS by a mean (‫ע‬standard deviation [SD]) of 0.38 ‫ע‬ 0.73 mg/dL ( ) and remained significantly elevated P ! .001 at 1 week after the last CMS dose (mean increase ‫ע‬ SD, 0.27 ‫ע‬ 0.57 mg/dL; ). The median creatinine level at last P p .001 CMS dose for patients who stopped therapy was 1.7 (range, 1.3-4.9). At 1 month after therapy, there was no difference in creatinine levels from baseline, with a mean (‫ע‬SD) difference of 0.04 ‫ע‬ 0.3 mg/dL ( ). The mean change in peak P p .34 creatinine level from baseline was 0.59 (range, Ϫ0.04 to 3.94).
Overall, 21% (95% confidence interval [CI], 13%-33%) of patients (including 1 patient who received both intravenous and inhaled CMS) stopped therapy secondary to nephrotoxicity, and 45% (95% CI, 34%-58%) met the RIFLE criteria for nephrotoxicity while receiving CMS at the time of their peak creatinine level. Table 3 shows the distribution of nephrotoxicity over time on the basis of the RIFLE criteria. No patients required RRT. Two patients had paresthesias attributed to CMS. Fifty-nine patients received CMS only intravenously, 5 received intravenous and inhaled CMS, and 2 received intravenous and intrathecal CMS. Figure 1 shows nephrotoxicity related to total CMS dose. Patients given CMS for 114 days were 3.7 times (95% CI, 1.3-10.3 times) more likely to meet risk, injury, or failure (R, I, or F) criteria. The incidence of nephrotoxicity was not affected by other variables (table 2). The overall frequency of proteinuria on urinalysis was 45% (95% CI, 31%-60%). For patients who had a nephrologist perform urine microscopy, 33% (4 of 12) and 42% (5 of 12) had muddy brown casts and renal tubular epithelial cells, respectively.
Discussion. Using the RIFLE criteria to define the incidence of acute renal failure associated with CMS treatment, the current study found that 45% of patients had some degree of renal dysfunction, and 21% of patients stopped therapy secondary to nephrotoxicity. This study is unique in that the patient population studied was a homogeneous cohort that is larger than most in previous studies, and the cohort had few comorbidities predisposing to renal dysfunction, which suggests that the results are reflective of the direct nephrotoxic effects of CMS.
Recent studies have used varying terminology to define nephrotoxicity and have reported mixed results, with nephrotoxicity rates in the range 7.4%-31% [5-9, 13, 18, 19] . These variable rates may be a reflection more of the definitions used than of the actual effects of CMS. For example, in one study, patients had mean increases in creatinine level of 0.27 mg/dL from baseline, which was similar to the increase observed in the current study (0.37 mg/dL) [9] , but they still would not have met the study's definition of nephrotoxicity (creatinine level 12 mg/dL for patients with baseline creatinine level !1.4 mg/ dL, a 50% increase in creatinine level for patients with baseline level 11.4 mg/dL, and/or the need for RRT). The use of the RI-FLE criteria in future studies of CMS will allow for more-accurate estimations of toxicity and comparisons among studies.
The available data suggest that, despite the common occurrence of mild renal dysfunction, the need for RRT, permanent kidney damage, and the need to stop therapy are uncommon among patients receiving CMS. In the current study, no patient required RRT, despite that several patients had evidence of acute tubular necrosis. One patient in the current study was able to complete therapy by dose reduction. This has been reported in other studies, but it remains to be determined whether dose reduction can consistently be done safely [9] .
A treatment cessation rate of 21% is higher than that in some previous reports [7, 9, 18] . The median day of stopping therapy in the current study was 13.5 (range, 8-37). The RIFLE scores of these patients (5R, 4I, 4F, and 1 with no score) suggest that therapy was stopped secondary to toxicity rather than them nearing the completion of their treatment courses. The disparate results between studies are likely multifactorial, but it is clear that, in some cases, CMS can lead to significant toxicity and the need for cessation of therapy.
Some reports-including the current study, which demonstrates a 4-fold increased risk of nephrotoxicity for patients receiving CMS for 114 days-suggest that toxicity is related to the total dose and duration of therapy [10, 19] , whereas other studies have not shown such an association [5, 7] . Nephrotoxicity does not appear to be associated with the dose per day (mg/kg/day), but rather with the total cumulative dose [10, 19] . Our results suggest that providers need to be prudent in monitoring creatinine levels in patients given CMS treatment for indications with prolonged courses.
The mechanisms of the renal toxicity of CMS are unknown, but some investigators have hypothesized that CMS induces membrane permeability and subsequent increases in intracellular cations, anions, and water, resulting in cell lysis [6, 20] . Tubular toxicity was suggested in our cohort by both the microscopic analysis of urine samples and the time course of renal recovery.
Limits to the current study include its retrospective design and the lack of a control group. However, this unique cohort demonstrates that mild renal dysfunction occurs in most patients treated with CMS but that permanent dysfunction is, fortunately, rare. The RIFLE criteria provide a useful framework to allow for comparison among future studies.
